Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390881 | 0.95 | MAPK14 (0.59) | MAPK14ACHEHTR4SIGMAR1HRH3 | |
| SCHEMBL3386122 | 0.92 | HRH3 (0.52) | MAPK14HRH3NPC1KDM4E | |
| SCHEMBL3386857 | 0.88 | HRH3 (0.52) | MAPK14HRH3NPC1KDM4E | |
| SCHEMBL3388657 | 0.87 | MAPK14 (0.60) | MAPK14ACHEHTR4SIGMAR1HRH3 | |
| SCHEMBL3390277 | 0.87 | MAPK14 (0.60) | MAPK14ACHEHTR4SIGMAR1HRH3 | |
| SCHEMBL3386153 | 0.85 | CHRM2 (0.45) | MAPK14ACHEHTR4HRH3CHRM2 | |
| SCHEMBL3391056 | 0.85 | MAPK14 (0.59) | MAPK14ACHEHTR4SIGMAR1CHRM2 | |
| SCHEMBL3383892 | 0.82 | MAPK14 (0.64) | MAPK14ACHEHTR4SIGMAR1HRH3 | |
| SCHEMBL3387941 | 0.81 | MAPK14 (0.53) | MAPK14ACHEHTR4SIGMAR1HRH3 | |
| SCHEMBL3388485 | 0.79 | MAPK14 (0.56) | MAPK14ACHEHTR4SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2029534-B1 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | MAPK14 3565/4885ACHE 22/4885HTR4 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.